GLP-1 portfolio powers another strong performance
25/11/21 -"Novo Nordisk reported strong Q3 results, with growth again driven by the GLP-1 diabetes portfolio and launch euphoria for Wegovy (obesity drug). Interestingly, management upgraded its 2021 guidance ..."
Pages
80
Language
English
Published on
25/11/21
You may also be interested by these reports :
07/12/21
According to media reports, CSL plans to acquire Vifor Pharma. Both firms operate in different therapeutic areas and, hence, there are no major ...
06/12/21
Omicron did not come fully out of the blue as we had pointed out the risk of new mutations coming from regions with lower vaccination rates. After ...
04/12/21
The recent surge of the more-contagious Omicron variant could result in delayed recovery for plasma supplies. Remember, with various preliminary ...
03/12/21
Given the multiple near-term challenges, including the DoJ investigation w.r.t Entresto (currently second-largest drug in terms of sales) and Omicron ...